Federal Contractor Profile
International Aids Vaccine Initiative INC.
Federal contracting record: $154M obligated across 31 awards from 2 agencies, FY 2016–2026.
Company Profile
Parent UEI (Unique Entity Identifier)
ZEJBC8JQM3P5
CAGE Code
44YM6
Address
125 BROAD ST FL 9TH, NEW YORK, NY, 100042743
First Federal Award
Jul 14, 2016
Most Recent Award
Aug 21, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$128M
83.0% of total obligations
- Department of Defense$26M
17.0% of total obligations
Top NAICS Activity
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 11, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | HHSN272201800010I IAVI STORAGE OF GMP AND NON-GMP MATERIALS FOR NIAID BASE AWARD, CAN 8470038 FOR $435,313.50 CAN 8040917 FOR $435,313.50 TOTAL $870,627 | $375K |
| Sep 2, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | 1800010I INTERNATIONAL AIDS VACCINE INITIATIVE TO V3 OBRA--2 BASE TASK ORDER FUNDING BIOD CAN 8470038 $642,953 | $679K |
| Jun 30, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | $385K |
| May 13, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | 1800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL | $89K |
| Apr 10, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | $3.4M |
| Aug 6, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN | $1.6M |
| Jul 31, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING | $70K |
| Jun 26, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | 1800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF HUMAN FLU CHALLENGE MATERIAL | $137K |
| May 13, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | $209K |
| Apr 17, 2024 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541715 | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | $960K |
| Dec 11, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING | $2.1M |
| Dec 7, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | $472K |
| Sep 26, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING | $1.5M |
| Sep 19, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | 1800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV) TOVM20V24VB 2 IID CAN 8470036 | $21K |
| Sep 13, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541712 | THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF | $382K |
| Aug 16, 2023 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541715 | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | $1.0M |
| Jul 21, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN | $18M |
| Jun 7, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541712 | THIS TASK ORDER IS TO DEVELOP AN OPTIMIZED PHASE 1 CGMP MANUFACTURING PROCESS FOR LIPID NANOPARTICLE (LNP) FABRICATION THAT ENABLE COVALENT COUPLING OF AN HIV-1 ENV TRIMER TO THE SURFACE OF THE LNP. A NON-GMP PROCESS RUN OF DRUG PRODUCT SHALL BE PERF | $253K |
| May 4, 2023 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541715 | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | $3.2M |
| Feb 8, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541714 | 1800010I IAVI BASE AWARD $810,077 FY20 CELL LINE OPTIMIZATION AND PRE-MASTER BANK GENERATION FOR SB 301, A VACCINE FOR HEPATITIS B VIRUS (HBV) TOVM20V24VB 2 IID CAN 8470036 | $190K |
| Jan 10, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN | $30M |
| Dec 1, 2022 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541715 | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | $1.1M |
| Sep 15, 2022 | Department of DefenseDEFENSE THREAT REDUCTION AGENCY | 541715 | ACCELERATED DEVELOPMENT OF A SARS-COV-2 VACCINE BASED ON THE LIVE VSVAG CHIMERIC VIRUS PLATFORM | $5.3M |
| Sep 12, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN | $17M |
| Aug 30, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | PRECLINICAL AND TRANSLATIONAL VACCINE DEVELOPMENT FOR HIV AND OTHER CANDIDATE AGENTS | $4.0M |
Want to win work like International Aids Vaccine Initiative INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.